Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi.
Yehia SalehAbdullah Al-AbchaOla AbdelkarimMahmoud AbdelnabiAbdallah AlmaghrabyNeal S KleimanPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2021)
Left ventricular thrombi form due to the presence of Virchow's triad in patients with left ventricular systolic dysfunction. This complication increases the incidence of systemic embolization, hence anticoagulation is recommended to decrease this risk. Up to the present time, vitamin K antagonists are recommended by all societal guidelines for patients with left ventricular thrombi. Recently, several studies have investigated the role of different anticoagulants and yielded promising outcomes. This opinion article focuses on the evidence supporting vitamin K antagonists and direct oral anticoagulants in patients with left ventricular thrombi.
Keyphrases
- left ventricular
- direct oral anticoagulants
- venous thromboembolism
- hypertrophic cardiomyopathy
- heart failure
- atrial fibrillation
- acute myocardial infarction
- cardiac resynchronization therapy
- aortic stenosis
- left atrial
- mitral valve
- oxidative stress
- adipose tissue
- risk factors
- coronary artery disease
- combination therapy
- transcatheter aortic valve replacement
- ejection fraction
- glycemic control
- case control
- replacement therapy